Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil

Detalhes bibliográficos
Autor(a) principal: Zahdi, Mariana Ribas
Data de Publicação: 2009
Outros Autores: Maluf Junior, Ivan, Maluf, Eliane Mara Cesario Pereira
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Medicina de Família e Comunidade (Online)
Texto Completo: https://www.rbmfc.org.br/rbmfc/article/view/420
Resumo: Objectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet.
id SBMFC-1_56940471c2e4cb71a14696dceff6a44d
oai_identifier_str oai:ojs.rbmfc.org.br:article/420
network_acronym_str SBMFC-1
network_name_str Revista Brasileira de Medicina de Família e Comunidade (Online)
repository_id_str
spelling Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, BrazilHepatite A: avaliação do custo-beneficio da prevenção pela vacina - Paraná, BrasilHepatitis AEpidemiologyVaccines Against Hepatitis ACost-Benefit AnalysisHepatite AEpidemiologiaVacinas Contra Hepatite AAnálise Custo-BeneficioObjectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet.Objetivos: conhecer a magnitude do problema da Hepatite A no Parana. , Brasil, e avaliar custo-beneficio davacinação. Materiais e métodos: o estudo é descritivo e de farmacoeconomia. Para avaliar a magnitude do problema,foram coletados dados sobre os casos de hepatite A do Sistema de Informação de Agravos de Notificação, (SIN AN),Sistema de Informação em Mortalidade (SIM) e Autorização de Internação Hospitalar (A114) da Secretaria de Estado daSaúde do Paraná ao período de 2000 a 2003. Foi estimada a probabilidade de uma coorte de crianças adquirirHepatite A durante a vida e os custos dos tratamentos. Esses gastos foram comparados corn o custo da vacinação.Resultados: foram 14.682 notificações das quais 12.102 (82,4%) ocorreram em menores de 15 anos. A incidência napopulação foi de 37,5/100000. Ocorreram 20 óbitos, sendo sete por insuficiência hepática. O custo com a doença foicomprovaciamente alto. 0 investimento para a vacinação de crianças, com duas doses (10 LTSD/dose), também foiestimado. Observou-se uma relação custo-beneficio positiva da vacinação. Para cada dólar investido na vacinação, 2,26LTSD sic) economizados no tratamento. Conclusões: os resultados confirmam a relação custo-beneficio positiva davacina. Sendo esse o primeiro estudo farmacoeconOmico sobre a vacinação contra hepatite A em nosso meio, apontasepara a necessidade de pesquisas mais aprofundadas e abrangentes, com o intuito de complementar alguns aspectosainda não explorados.Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)2009-11-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos Originais; Original Articlesapplication/pdfhttps://www.rbmfc.org.br/rbmfc/article/view/42010.5712/rbmfc4(16)420Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 No. 16 (2009); 281-288Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 Núm. 16 (2009); 281-288Revista Brasileira de Medicina de Família e Comunidade; v. 4 n. 16 (2009); 281-2882179-79941809-5909reponame:Revista Brasileira de Medicina de Família e Comunidade (Online)instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)instacron:SBMFCporhttps://www.rbmfc.org.br/rbmfc/article/view/420/324Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Malufinfo:eu-repo/semantics/openAccessZahdi, Mariana RibasMaluf Junior, IvanMaluf, Eliane Mara Cesario Pereira2020-05-21T20:22:21Zoai:ojs.rbmfc.org.br:article/420Revistahttp://www.rbmfc.org.br/index.php/rbmfchttps://www.rbmfc.org.br/rbmfc/oai||david@sbmfc.org.br2179-79941809-5909opendoar:2020-05-21T20:22:21Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)false
dc.title.none.fl_str_mv Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
Hepatite A: avaliação do custo-beneficio da prevenção pela vacina - Paraná, Brasil
title Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
spellingShingle Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
Zahdi, Mariana Ribas
Hepatitis A
Epidemiology
Vaccines Against Hepatitis A
Cost-Benefit Analysis
Hepatite A
Epidemiologia
Vacinas Contra Hepatite A
Análise Custo-Beneficio
title_short Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
title_full Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
title_fullStr Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
title_full_unstemmed Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
title_sort Hepatitis A: an assessment of the cost-benefit ratio of prevention by the vaccine - Paraná, Brazil
author Zahdi, Mariana Ribas
author_facet Zahdi, Mariana Ribas
Maluf Junior, Ivan
Maluf, Eliane Mara Cesario Pereira
author_role author
author2 Maluf Junior, Ivan
Maluf, Eliane Mara Cesario Pereira
author2_role author
author
dc.contributor.author.fl_str_mv Zahdi, Mariana Ribas
Maluf Junior, Ivan
Maluf, Eliane Mara Cesario Pereira
dc.subject.por.fl_str_mv Hepatitis A
Epidemiology
Vaccines Against Hepatitis A
Cost-Benefit Analysis
Hepatite A
Epidemiologia
Vacinas Contra Hepatite A
Análise Custo-Beneficio
topic Hepatitis A
Epidemiology
Vaccines Against Hepatitis A
Cost-Benefit Analysis
Hepatite A
Epidemiologia
Vacinas Contra Hepatite A
Análise Custo-Beneficio
description Objectives: know the mqgniulde of the problem of Hepatitis A in Parana, Brazil, and assess the cost-benefit ratio of vaccination. Materials and methods: the study is descriptive and pharmacoeconomical. To assess the magnitude of the problem, data were collected on cases of hepatitis A from the Information System of Worsening Notification (SINAN), Information System in Mortality (SIM) and Hospitalization Authorization (AIH) of the State Secretariat of I Health of Paraná referring to the period from 2000 to 2003. The probability of one tenth of children acquiring Hepatitis A during their lifetime was estimated along with the costs of the treatments. These expenses were compared with the cost of vaccination. Results: there were 14,682 notices of which 12,102 (82.4%) occurred in children under 15 years of age. The incidence on the population was 37.5/100000. There were 20 deaths, being 7 due to liver failure. Costs with the disease were truly high.. The investment in children vaccination, with two doses (10 USD / dose), was also estimated. A positive cost-benefit relation of the vaccination was observed. For each dollar invested in vaccination, US$ 2.26 are saved on the treatment. Conclusions: the results confirm the positive cost-benefit relation of the vaccine. Since this is the first pharmacoeconomic study on vaccination against hepatitis A in our environment, the need for more in-depth and encompassing studies is highlighted with the goal of complementing a few aspects not explored yet.
publishDate 2009
dc.date.none.fl_str_mv 2009-11-17
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos Originais; Original Articles
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.rbmfc.org.br/rbmfc/article/view/420
10.5712/rbmfc4(16)420
url https://www.rbmfc.org.br/rbmfc/article/view/420
identifier_str_mv 10.5712/rbmfc4(16)420
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.rbmfc.org.br/rbmfc/article/view/420/324
dc.rights.driver.fl_str_mv Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Maluf
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2009 Mariana Ribas Zahdi, Ivan Maluf Junior, Eliane Mara Cesario Pereira Maluf
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)
publisher.none.fl_str_mv Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)
dc.source.none.fl_str_mv Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 No. 16 (2009); 281-288
Revista Brasileira de Medicina de Família e Comunidade; Vol. 4 Núm. 16 (2009); 281-288
Revista Brasileira de Medicina de Família e Comunidade; v. 4 n. 16 (2009); 281-288
2179-7994
1809-5909
reponame:Revista Brasileira de Medicina de Família e Comunidade (Online)
instname:Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)
instacron:SBMFC
instname_str Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)
instacron_str SBMFC
institution SBMFC
reponame_str Revista Brasileira de Medicina de Família e Comunidade (Online)
collection Revista Brasileira de Medicina de Família e Comunidade (Online)
repository.name.fl_str_mv Revista Brasileira de Medicina de Família e Comunidade (Online) - Sociedade Brasileira de Medicina de Família e Comunidade (SBMFC)
repository.mail.fl_str_mv ||david@sbmfc.org.br
_version_ 1752122105889030144